{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:55:22Z","timestamp":1781585722126,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lassa virus is endemic in many West African countries and has significant epidemic\/pandemic potential. The Coalition for Epidemic Preparedness Innovations (CEPI) Centralized Laboratory Network (CLN) is developing validated, harmonized methods to support and accelerate vaccine development in the event of an outbreak. We present here the development and validation of an assay to quantify anti-Lassa virus neutralizing antibodies. As the method uses a pseudotyped virus (PV) instead of authentic Lassa virus\u2014a pathogen listed as hazard group 4\u2014it can be performed at a lower containment level, making it widely accessible especially in those regions where Lassa fever is circulating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A recombinant vesicular stomatitis virus (rVSV)-based pseudotyped virus neutralization assay (PVNA) was developed. A working standard was prepared and calibrated against the International Standard (IS) for Lassa virus neutralizing antibodies, enabling results to be expressed in International Units. The method was validated according to the International Council for Harmonisation (ICH) Q2(R2) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The rVSV-based PVNA was successfully developed and validated. The analytical range of the assay was established as 10\u2013100 IU\/mL, and seropositive samples from a Lassa vaccine clinical trial fell within this range. Results from the PVNA showed direct correlation with results obtained from authentic virus neutralization methods. The method was, therefore, concluded to be fit-for-purpose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We have successfully developed and validated a PVNA for the quantification of neutralizing antibodies against Lassa virus. We have also provided a practical example of how to calibrate a serological method to the WHO International Standard to achieve greater harmonization and comparability between studies. The method is now being transferred to partner laboratories within the CLN to enable harmonized testing of clinical trial samples and support the development and evaluation of Lassa vaccine candidates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1783813","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:29:09Z","timestamp":1781584149000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a pseudotyped virus neutralization assay for quantification of anti-Lassa virus neutralizing antibodies"],"prefix":"10.3389","volume":"17","author":[{"given":"Edward T.","family":"Mee","sequence":"first","affiliation":[{"name":"High Consequence Pathogens (R&D), Medicines and Healthcare products Regulatory Agency","place":["South Mimms, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Bentley","sequence":"additional","affiliation":[{"name":"High Consequence Pathogens (R&D), Medicines and Healthcare products Regulatory Agency","place":["South Mimms, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gathoni","family":"Kamuyu","sequence":"additional","affiliation":[{"name":"Coalition for Epidemic Preparedness Innovations","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Guerrini","sequence":"additional","affiliation":[{"name":"High Consequence Pathogens (R&D), Medicines and Healthcare products Regulatory Agency","place":["South Mimms, United Kingdom"]},{"name":"VisMederi Srl","place":["Siena, Italy"]},{"name":"Department of Life Sciences, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Azizi","sequence":"additional","affiliation":[{"name":"Coalition for Epidemic Preparedness Innovations","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Mattiuzzo","sequence":"additional","affiliation":[{"name":"High Consequence Pathogens (R&D), Medicines and Healthcare products Regulatory Agency","place":["South Mimms, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","unstructured":"Priority pathogens"},{"key":"B2","article-title":"Pathogens prioritization: A scientific framework for epidemic and pandemic research preparedness","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2501073","article-title":"Safety and immunogenicity of an rVSV Lassa fever vaccine candidate","volume":"393","author":"Malkin","year":"2025","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01278-22","article-title":"Neutralizing antibodies against Lassa virus lineage I","volume":"13","author":"Buck","year":"2022","journal-title":"mBio"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v13020217","article-title":"More than just gene therapy vectors: Lentiviral vector pseudotypes for serological investigation","volume":"13","author":"Toon","year":"2021","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13081785","article-title":"Exploring the use of viral vectors pseudotyped with viral glycoproteins as tools to study antibody-mediated neutralizing activity","volume":"13","author":"Ramos-Cela","year":"2025","journal-title":"Microorganisms"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1184362","article-title":"Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature","volume":"14","author":"Cantoni","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00982-x","article-title":"The CEPI centralised laboratory network: Supporting COVID-19 vaccine development","volume":"397","author":"Kumar","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404309","article-title":"Unifying global efforts by CEPI's centralized laboratory network","volume":"15","author":"Azizi","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2561458","article-title":"Future directions in combating outbreaks at CEPI Centralized Laboratory Network","volume":"21","author":"Azizi","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(23)00324-5","article-title":"Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: A qualification analysis","volume":"5","author":"Manak","year":"2024","journal-title":"Lancet Microbe"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2344249","article-title":"Driving consistency: CEPI-Centralized Laboratory Network's conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines","volume":"20","author":"Azizi","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02534-x","article-title":"The CEPI centralized laboratory network for COVID-19 will help prepare for future outbreaks","volume":"29","author":"Azizi","year":"2023","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03367-y","article-title":"Preparedness and priority research to tackle the mpox outbreak response","volume":"31","author":"Azizi","year":"2025","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41541-023-00692-0","article-title":"Availability and use of standards in vaccine development","volume":"8","author":"Avumegah","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/v11090781","article-title":"The role of reference materials in the research and development of diagnostic tools and treatments for haemorrhagic fever viruses","volume":"11","author":"Mattiuzzo","year":"2019","journal-title":"Viruses"},{"key":"B17","unstructured":"Providing International biological reference preparations"},{"key":"B18","article-title":"Establishment of the first WHO International Standard and Reference Panel for anti-Lassa Fever virus antibody","volume-title":"WHO\/BS\/2021.2406","author":"Mattiuzzo","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.12688\/f1000research.149578.2","article-title":"A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison","volume":"13","author":"Antonelli","year":"2024","journal-title":"F1000Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28580","DOI":"10.1038\/s41598-025-11362-7","article-title":"Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors","volume":"15","author":"McCormack","year":"2025","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248348","article-title":"Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2","volume":"16","author":"Neerukonda","year":"2021","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2210\/pdb3lpt\/pdb","article-title":"Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV","volume":"95","author":"De La Torre-Tarazona","year":"2023","journal-title":"J Med Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"},{"key":"B25","volume-title":"Statistical method in biological assay","author":"Finney","year":"1978"},{"key":"B26","article-title":"Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody","author":"Mattiuzzo","year":"2020","journal-title":"WHO Expert Committee Biol Standardizat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/mps1010008","article-title":"Pseudotype neutralization assays: From laboratory bench to data analysis","volume":"1","author":"Ferrara","year":"2018","journal-title":"Methods Protoc"},{"key":"B28","article-title":"Validation of analytical procedures Q2(R2)","volume-title":"International council for harmonisation of technical requirements for pharmaceurticals for human use","year":"2023"},{"key":"B29","article-title":"WHO manual for the preparation of reference materials for use as secondary standards in antibody testing","volume-title":"World health organization","year":"2022"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14111129","article-title":"Pseudovirus-based neutralization assays as customizable and scalable tools for serological surveillance and immune profiling","volume":"14","author":"Denani","year":"2025","journal-title":"Pathogens"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2026.2640285","article-title":"Evaluation of candidate reference materials for the harmonization of Lassa fever serology","volume":"15","author":"Bentley","year":"2026","journal-title":"Emerg Microbes Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:29:18Z","timestamp":1781584158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1783813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1783813"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1783813","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1783813"}}